Saito I, Suzuki A, Saiko Y, Yokozawa M, Ono K
Department of Clinical Laboratory, Tokyo Kyosai Hospital.
Hinyokika Kiyo. 1992 May;38(5):629-32.
We performed basic and clinical studies in male gonococcal urethritis on a new oral antimicrobial agent, levofloxacin (LVFX, DR-3355), a new quinolone derivative. The antibacterial activity of LVFX against clinical strains of Neisseria gonorrhoeae was roughly comparable to that of ofloxacin, and ciprofloxacin. LVFX was administered to 10 males with gonococcal urethritis, 200 mg twice a day (8 cases) or 100 mg twice a day for 3 days (2 cases). Clinical evaluation was made according to the criteria of the Japanese UTI Committee. Overall efficacy rate was 100% (10/10). In the complication of chlamydia trachomatis (2 cases), efficacy rate was 100% (2/2). No subjective or objective adverse reactions occurred.
我们对一种新型口服抗菌药物左氧氟沙星（LVFX，DR - 3355，一种新型喹诺酮衍生物）进行了男性淋菌性尿道炎的基础和临床研究。LVFX对淋病奈瑟菌临床菌株的抗菌活性与氧氟沙星和环丙沙星大致相当。对10例男性淋菌性尿道炎患者给予LVFX，每日2次，每次200mg（8例）或每日2次，每次100mg，共3天（2例）。根据日本泌尿道感染委员会的标准进行临床评估。总有效率为100%（10/10）。在沙眼衣原体并发症（2例）中，有效率为100%（2/2）。未出现主观或客观不良反应。
